维生素K与慢性肾脏病患者心血管并发症
本文综述维生素K(尤其K2)在慢性肾脏病(CKD)患者心血管钙化中的作用。观察性研究提示维生素K缺乏或摄入不足与心血管钙化进展、发病和死亡相关。高剂量维生素K2(menaquinone 7)可降低终末期肾病患者循环非活性基质Gla蛋白水平,但多项随机对照试验未能证实心血管获益,本文讨论原因与对策。
要点
- CKD患者因饮食限制和可能的维生素K循环受损而易缺乏维生素K。
- 观察性研究显示维生素K缺乏或低摄入与心血管钙化进展及不良预后相关。
- 高剂量menaquinone 7可降低终末期肾病患者循环非活性MGP,但RCT未证实心血管获益。
核心结论
- 观察性数据支持维生素K缺乏与CKD心血管钙化及不良预后相关,但高剂量menaquinone 7的RCT未证实心血管获益。
研究设计与样本
- 本文为综述,聚焦维生素K(尤其K2)在CKD患者心血管钙化中的作用。
主要发现
- 多个观察性研究将相对维生素K缺乏或低摄入与心血管钙化进展、发病和死亡相关联。
- 晚期CKD患者特别易缺乏维生素K,部分因饮食限制,也可能因内源性维生素K循环受损。
- 高剂量膳食补充维生素K2(尤其menaquinone 7)可有效降低终末期肾病患者循环去磷酸化未羧化(即非活性)基质Gla蛋白水平。
- 多项高剂量menaquinone 7补充的随机对照试验在晚期CKD患者中未能证实心血管获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vitamin K, well known for its role in coagulation, encompasses 2 major subgroups: vitamin K1 is exclusively synthesized by plants, whereas vitamin K2 mostly originates from bacterial synthesis. Vitamin K serves as a cofactor for the enzyme γ-glutamyl carboxylase, which carboxylates and thereby activates various vitamin K-dependent proteins. Several vitamin K-dependent proteins are synthesized in bone, but the role of vitamin K for bone health in chronic kidney disease patients, in particular the prevention of osteoporosis, is still not firmly established. Herein, we focus on another prominent action of vitamin K, in particular vitamin K2 (namely, the activation of matrix γ-carboxyglutamic acid protein, the most potent inhibitor of cardiovascular calcifications). Multiple observational studies link relative vitamin K deficiency or low intake to cardiovascular calcification progress, morbidity, and mortality. Patients with advanced chronic kidney disease are particularly vitamin K deficient, in part because of dietary restrictions but possibly also due to impaired endogenous recycling of vitamin K. At the same time, this population is characterized by markedly accelerated cardiovascular calcifications and mortality. High-dose dietary supplementation with vitamin K2, in particular the most potent form, menaquinone 7, can potently reduce circulating levels of dephosphorylated uncarboxylated (i.e., inactive matrix γ-carboxyglutamic acid protein) in patients with end-stage kidney disease. However, despite this compelling data basis, several randomized controlled trials with high-dose menaquinone 7 supplements in patients with advanced chronic kidney disease have failed to confirm cardiovascular benefits. Herein, we discuss potential reasons and solutions for this.
引用
- Kaesler N, Schurgers LJ, Floege J, et al. Vitamin K and cardiovascular complications in chronic kidney disease patients. Kidney Int. 2021. PMID: 34310988. doi:10.1016/j.kint.2021.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。